ICON (ICLR) Q3 2026 Earnings Call Transcript
ICON (ICLR) reported Q3 2026 earnings with adjusted EBITDA of $337M, adjusted EPS of $2.66, and $300M in free cash flow. Revenue was $2B, down 2.9% YoY. Gross business wins rose 27% YoY, and net business wins hit a record $3.15B. The company highlighted strong performance in large pharma, midsized pharma, and biotech sectors, along with improvements in gross margin and cash generation.
How this was made

The 30-second read
Why it matters
Earnings beat expectations on margin and cash flow, likely prompting short‑term buying pressure.
Market read
First disclosure of ICON's Q3 2026 earnings provides fresh data for traders; the combination of strong cash flow and a sizable buyback creates a bullish catalyst.
What to watch
Potential impact of the Symphony divestiture on future revenue mix and integration costs.
Background
ICON plc reported its Q3 2026 results, highlighting cash generation, margin expansion, and a $400M share repurchase.
Ticker impact
Q3 2026 earnings disclosed adjusted EBITDA $337M, EPS $2.66, revenue just over $2B and a $400M share repurchase.
likely modest upside as investors price in strong cash flow and share repurchase.
First report of earnings with better-than-expected margins and a large buyback typically supports the stock.
Market effects
Positive for the CRO/clinical research services sector, reinforcing demand trends.
Supports broader US healthcare services sentiment.
Limited to investors tracking mid‑cap pharma services firms.
Counterpoint
If revenue decline continues, the buyback may be seen as a defensive move, limiting upside.
Key entities
- ExecutiveBarry Balfe
CEO of ICON who presented the earnings call.
- ExecutiveNigel Clerkin
CFO who detailed the financial metrics.


